Multiple Sclerosis Research in Europe

1. Front Matter

   Pages i-xxxiii

   PDF

2. Clinical Studies

   1. Front Matter

      Pages 1-1

      PDF

   2. Clinical Studies in Multiple Sclerosis

      • S. Poser

      Pages 3-12

   3. Clinical Trials

      • Peter Rudge

      Pages 13-14

   4. Onset, Course and Prognosis of Multiple Sclerosis

      • C. Confavreux

      Pages 15-30

   5. A Comparative Study between Multiple Sclerosis Out-patients and In-patients staying at a specialized Multiple Sclerosis Clinic

      • R. Medaer, M. Puystjens, H. Callaert

      Pages 31-40

   6. Incapacity and Disability in Multiple Sclerosis

      • J. M. Minderhoud, A. J. A. Prange, H. Dassel

      Pages 41-44

   7. Immunosuppression with Cyclophosphamide in Multiple Sclerosis Patients

      • R. E. Gonsette, L. Demonty

      Pages 45-48

   8. Anti-Lymphocyte Serum in Severe Multiple Sclerosis

      • R. Marteau, F. Lhermitte, H. De Saxce

      Pages 49-53

   9. Long-term Prescription of Azathioprine in Multiple Sclerosis. A Review of Published Series

      • O. Sabouraud, M. Mérienne

      Pages 55-59

   10. Azathioprine Assessment in Progressive Multiple Sclerosis. Clinical Aspects

       • I. E. Zeeberg

       Pages 61-70

   11. Dietary Therapy in Multiple Sclerosis

       • D. Bates

       Pages 71-79

   12. An 8 Years Follow-up Study of Transfer Factor Treatment on the Course of Multiple Sclerosis

       • A. M. Nordenbo, I. Zeeberg

       Pages 81-83

   13. Compact Manual for Multiple Sclerosis Registration in Clinical Research

       • O. Andersen, M. Andersson, T. Broman, I. Zeeberg

       Pages 85-93

   14. Comparison of Multiple Sclerosis Incidence Clinical and ABR Data Indicates a Higher Degree of Dissemination of Lesions in a Progressive than in a Remitting Course

       • O. Andersen, U. Rosenhall, B. Runmarker

       Pages 95-99

3. Immunology

   1. Front Matter

      Pages 101-101

      PDF

   2. Multiple Sclerosis and Immunity: Facts, Fiction and Future Development

      • J. Mertin

      Pages 103-107

   3. The Spectrum of Experimental Allergic Encephalomyelitis

      • H. Lassmann, K. Vass

      Pages 109-113

   4. T-cell Subsets in Multiple Sclerosis

      • M. A. Bach, E. Tournier-Lasserve

      Pages 115-122

   5. Functional Differences between Cerebrospinal Fluid and Peripheral Blood T-cells in Multiple Sclerosis

      • M. S. Wollheim, E. C. Defreitas

      Pages 123-130

Multiple sclerosis is an unique disease with a tremendous impact on social life in countries with moderate climates. Its cause is unknown. In recent years however hopes have been raised that the disease might be fought, and possibly cured. With the disappearance of poliomyelitis as the main paralyzing disease multiple sclerosis has taken its place as the single disease that is responsible for paralyzing the young with an incurable affliction of long duration, for social disruption and for an 1 economic impact that is estimated to be higher than heart disease • A multi-national, mUlti-disciplinary approach to this extremely disabling disease is urgently needed in this phase of hopeful scientific developments. The Commission of the European Communities therefore sponsored a Con­ ference on Multiple Sclerosis Research in Europe on 29,30 and 31 January 1985 in Nijmegen, The Netherlands, with the aim of formulating practical proposals for such cooperation in the Communities. This volume contains the papers read at that conference.

• Public Health
• assessment
• biochemistry
• biology
• brain
• cell
• chemistry
• clinic
• diagnosis
• immunology
• infection
• neurobiology
• neurophysiology
• physiology
• therapy

• Department of Neurology, Radboud University Hospital, Nijmegen, The Netherlands

  Otto R. Hommes

Policies and ethics